New hope for rare leukemia: drug ABC008 shows promise in early trial

NCT ID NCT05532722

Completed Disease control Sponsor: Abcuro, Inc. Source: ClinicalTrials.gov ↗

First seen May 16, 2026 · Last updated May 16, 2026

Summary

This study tested a new drug called ABC008 in 21 adults with a rare leukemia called T-LGLL. The main goal was to check the drug's safety and find the right dose. Researchers also looked at how the drug affected blood counts and other lab results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope

Duarte, California, 91010, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, 84112, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
The University of Texas M.D. Anderson Cancer Center

Houston, Texas, 77030, United States
University of Southern California

Los Angeles, California, 90033, United States

Conditions

Explore the condition pages connected to this study.

T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA